Literature DB >> 21875078

Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion.

May Khanna1, Fang Wang, Inha Jo, W Eric Knabe, Sarah M Wilson, Liwei Li, Khuchtumur Bum-Erdene, Jing Li, George W Sledge, Rajesh Khanna, Samy O Meroueh.   

Abstract

Interaction of the urokinase receptor (uPAR) with its binding partners such as the urokinase-type plasminogen activator (uPA) at the cell surface triggers a series of proteolytic and signaling events that promote invasion and metastasis. Here, we report the discovery of a small molecule (IPR-456) and its derivatives that inhibit the tight uPAR·uPA protein-protein interaction. IPR-456 was discovered by virtual screening against multiple conformations of uPAR sampled from explicit-solvent molecular dynamics simulations. Biochemical characterization reveal that the compound binds to uPAR with submicromolar affinity (K(d) = 310 nM) and inhibits the tight protein-protein interaction with an IC(50) of 10 μM. Free energy calculations based on explicit-solvent molecular dynamics simulations suggested the importance of a carboxylate moiety on IPR-456, which was confirmed by the activity of several derivatives including IPR-803. Immunofluorescence imaging showed that IPR-456 inhibited uPA binding to uPAR of breast MDA-MB-231 tumor cells with an IC(50) of 8 μM. The compounds blocked MDA-MB-231 cell invasion, but IPR-456 showed little effect on MDA-MB-231 migration and no effect on adhesion, suggesting that uPAR mediates these processes through its other binding partners.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21875078      PMCID: PMC3220747          DOI: 10.1021/cb200180m

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  49 in total

1.  Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation.

Authors:  Araz Jakalian; David B Jack; Christopher I Bayly
Journal:  J Comput Chem       Date:  2002-12       Impact factor: 3.376

2.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes.

Authors:  Holger Gohlke; Christina Kiel; David A Case
Journal:  J Mol Biol       Date:  2003-07-18       Impact factor: 5.469

3.  Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules.

Authors:  Michael H A Roehrl; Sunghyun Kang; José Aramburu; Gerhard Wagner; Anjana Rao; Patrick G Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-06       Impact factor: 11.205

Review 4.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

5.  Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites.

Authors:  Henrik Gårdsvoll; Finn Werner; Leif Søndergaard; Keld Danø; Michael Ploug
Journal:  Protein Expr Purif       Date:  2004-04       Impact factor: 1.650

6.  A detergent-based assay for the detection of promiscuous inhibitors.

Authors:  Brian Y Feng; Brian K Shoichet
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

7.  Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

Authors:  Milan Bruncko; Thorsten K Oost; Barbara A Belli; Hong Ding; Mary K Joseph; Aaron Kunzer; Darlene Martineau; William J McClellan; Michael Mitten; Shi-Chung Ng; Paul M Nimmer; Tilman Oltersdorf; Cheol-Min Park; Andrew M Petros; Alexander R Shoemaker; Xiaohong Song; Xilu Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg; Steven W Elmore
Journal:  J Med Chem       Date:  2007-01-26       Impact factor: 7.446

Review 8.  Flexible ligand docking to multiple receptor conformations: a practical alternative.

Authors:  Maxim Totrov; Ruben Abagyan
Journal:  Curr Opin Struct Biol       Date:  2008-02-25       Impact factor: 6.809

Review 9.  Principles of protein-protein interactions: what are the preferred ways for proteins to interact?

Authors:  Ozlem Keskin; Attila Gursoy; Buyong Ma; Ruth Nussinov
Journal:  Chem Rev       Date:  2008-03-21       Impact factor: 60.622

10.  Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles.

Authors:  R L Shapiro; J G Duquette; I Nunes; D F Roses; M N Harris; E L Wilson; D B Rifkin
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

View more
  25 in total

1.  Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor.

Authors:  Fang Wang; W Eric Knabe; Liwei Li; Inha Jo; Timmy Mani; Hartmut Roehm; Kyungsoo Oh; Jing Li; May Khanna; Samy O Meroueh
Journal:  Bioorg Med Chem       Date:  2012-06-12       Impact factor: 3.641

2.  Small-molecule CaVα1⋅CaVβ antagonist suppresses neuronal voltage-gated calcium-channel trafficking.

Authors:  Xingjuan Chen; Degang Liu; Donghui Zhou; Yubing Si; David Xu; Christopher W Stamatkin; Mona K Ghozayel; Matthew S Ripsch; Alexander G Obukhov; Fletcher A White; Samy O Meroueh
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-24       Impact factor: 11.205

Review 3.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

4.  Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.

Authors:  Degang Liu; David Xu; Min Liu; William Eric Knabe; Cai Yuan; Donghui Zhou; Mingdong Huang; Samy O Meroueh
Journal:  Biochemistry       Date:  2017-03-17       Impact factor: 3.162

5.  Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.

Authors:  Timmy Mani; Fang Wang; William Eric Knabe; Anthony L Sinn; May Khanna; Inha Jo; George E Sandusky; George W Sledge; David R Jones; Rajesh Khanna; Karen E Pollok; Samy O Meroueh
Journal:  Bioorg Med Chem       Date:  2013-01-09       Impact factor: 3.641

6.  Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor.

Authors:  Timmy Mani; Degang Liu; Donghui Zhou; Liwei Li; William Eric Knabe; Fang Wang; Kyungsoo Oh; Samy O Meroueh
Journal:  ChemMedChem       Date:  2013-10-02       Impact factor: 3.466

Review 7.  Oncogenic protein interfaces: small molecules, big challenges.

Authors:  Tracy L Nero; Craig J Morton; Jessica K Holien; Jerome Wielens; Michael W Parker
Journal:  Nat Rev Cancer       Date:  2014-03-13       Impact factor: 60.716

8.  A novel peptide blocking cancer cell invasion by structure-based drug design.

Authors:  Yuki Yamada; Seiji Kanayama; Fuminori Ito; Noriyuki Kurita; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-07-31

9.  Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor.

Authors:  Anthony F Rullo; Kelly J Fitzgerald; Viswanathan Muthusamy; Min Liu; Cai Yuan; Mingdong Huang; Minsup Kim; Art E Cho; David A Spiegel
Journal:  Angew Chem Int Ed Engl       Date:  2016-02-16       Impact factor: 15.336

10.  A flexible multidomain structure drives the function of the urokinase-type plasminogen activator receptor (uPAR).

Authors:  Haydyn D T Mertens; Magnus Kjaergaard; Simon Mysling; Henrik Gårdsvoll; Thomas J D Jørgensen; Dmitri I Svergun; Michael Ploug
Journal:  J Biol Chem       Date:  2012-08-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.